Snehal Patel Purchases 1,100 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,100 shares of the stock in a transaction on Friday, July 24th. The shares were purchased at an average price of $12.88 per share, with a total value of $14,168.00. Following the acquisition, the chief executive officer directly owned 5,607,702 shares in the company, valued at $72,227,201.76. This represents a 0.02% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Monday, July 27th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $13.62 per share, for a total transaction of $20,430.00.
• On Thursday, July 23rd, Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $13.14 per share, for a total transaction of $32,850.00.

Greenwich LifeSciences Trading Down 5.1%

Greenwich LifeSciences stock opened at $12.77 on Thursday. The company has a fifty day simple moving average of $21.34 and a 200-day simple moving average of $24.20. The stock has a market cap of $187.46 million, a P/E ratio of -8.13 and a beta of 1.40. Greenwich LifeSciences, Inc. has a 12-month low of $7.78 and a 12-month high of $34.10.

Analyst Ratings Changes

A number of analysts have issued reports on GLSI shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Friday, May 15th. HC Wainwright raised their target price on Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen cut Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Greenwich LifeSciences has an average rating of “Hold” and an average target price of $57.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in shares of Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after purchasing an additional 1,322 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after purchasing an additional 3,168 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Greenwich LifeSciences by 109.6% in the 4th quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after purchasing an additional 4,102 shares during the last quarter. Strs Ohio acquired a new stake in shares of Greenwich LifeSciences in the 1st quarter valued at about $177,000. Finally, Jane Street Group LLC acquired a new stake in shares of Greenwich LifeSciences in the 4th quarter valued at about $203,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.